The American Journal of Medicine
Volume 119, Issue 10 , Pages 877-883 , October 2006

Thoracic Empyema in Patients with Community-Acquired Pneumonia

Received 24 October 2005 ,Accepted 20 March 2006.

References 

  1. Light RW, Girard WM, Jenkinson SG, George RB. Parapneumonic effusions. Am J Med. 1980;69:507–512
  2. Alfageme I, Munoz F, Pena N, et al. Empyema of the thorax in adults: etiology, microbiological findings, and management. Chest. 1993;103:839–843
  3. Kearney SE, Davies CW, Davies RJ, et al. Pleural infections: commuted tomography and ultrasound in parapneumonic effusions and empyema. Clin Radiol. 2000;55:542–547
  4. Sahn SA. Management of complicated parapneumonic effusions. Am Rev Respir Dis. 1993;148:813–817
  5. Davies CW, Kearney SE, Gleeson FV, Davies RJ. Predictors of outcome and long-term survival in patients with pleural infection. Am J Respir Crit Care Med. 1999;160:1682–1687
  6. Ferguson AD, Prescott RJ, Selkon JB, Watson D, Swinburn CR. The clinical course and management of thoracic empyema. QJM. 1996;89:285–289
  7. Marrie TJ, Lau CY, Wheeler SL, et al. A controlled trial of a critical pathway for treatment of community acquired pneumonia. JAMA. 2000;283:749–755
  8. Marrie TJ, Wu L. Factors influencing in-hospital mortality in community-acquired pneumonia: a prospective study of patients not initially admitted to the ICU. Chest. 2005;127:1260–1270
  9. Hanna JW, Reed JC, Choplin RA. Pleural infections: a clinical radiographic review. J Thorac Imaging. 1991;6:68–79
  10. BTS Research Committee. Community acquired pneumonia in adults in British hospitals (A survey of aetiology, mortality, prognostic factors and outcomes). Q J Med. 1987;62:195–220
  11. Maskell NA, Davies CW, Nunn AJ, et al. UK controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med. 2005;352:865–874
  12. Aquino SL, Webb WR, Gushiken BJ. Pleural exudates and transudates: diagnosis with contrast enhanced CT. Radiology. 1994;192:803–808
  13. Evans AL, Gleeson FV. Radiology in pleural disease: state of the art. Respirology. 2004;9(3):300–312
  14. Findland M, Barnes MW. Changing ecology of acute bacterial empyema: occurrence and mortality at Boston City Hospital during 12 selected years from 1935-1972. J Infect Dis. 1978;137:274–291
  15. Bartlett JG. Anaerobic bacterial pleuro-pulmonary infections. Semin Respir Crit Care Med. 1992;13:158–166
  16. Wong CA, Donald F, Macfarlane JT. Streptococcus milleri pulmonary disease: a review and clinical description of 25 patients. Thorax. 1995;50:1093–1096
  17. Shinzato T, Saito A. The Streptococcus milleri group as a cause of pulmonary infections. Clin Infect Dis. 1995;21:S238–S243
  18. Lindstrom S, Kolbe J. Community acquired parapneumonic thoracic empyema: predictors of outcome. Respirology. 1999;4:173
  19. Jacobs JA, Stobberingh EE. In-vitro antimicrobial susceptibility of the “Streptococcus milleri” group. J Antimicrob Chemother. 1996;37:371–375
  20. Lima A, Jimenez ML, Alarcon T, Lopez-Brea M. Five year analysis of antimicrobial susceptibility of the Streptococcus milleri group. Eur J Clin Microbiol Infect Dis. 1999;18:440–444
  21. Bantar C, Canigia LF, Relloso S, et al. Species belonging to the Streptococcus milleri group: antimicrobial susceptibility and comparative prevalence in significant clinical specimens. J Clin Microbiol. 1996;34:2020–2022

PII: S0002-9343(06)00599-7

doi: 10.1016/j.amjmed.2006.03.042

The American Journal of Medicine
Volume 119, Issue 10 , Pages 877-883 , October 2006

Article Tools

* Image Usage & Resolution